Comparing two treatments for intermediate-stage liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of Transarterial Tirapazamine Embolization (TATE) compared to conventional Transarterial Chemoembolization (cTACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). The study will enroll patients who meet specific eligibility criteria, including those with no evidence of extrahepatic metastasis and adequate organ function. By comparing these two treatment approaches, the trial seeks to provide insights into the potential advantages of TATE as a novel therapeutic option for HCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with primary hepatocellular carcinoma according to AASLD criteria.
* No evidence of extrahepatic metastasis, regional lymph node involvement, or vascular tumor thrombus.
* Patients must be eligible for TAE or TACE treatment.
* ECOG ≤ 1.
* Child-Pugh score ≤ 7.
* Adequate bone marrow, liver, and kidney function is required.

Exclusion Criteria:

* History of liver transplantation.
* Previous radioemblization or radiotherapy for liver tumors.
* severe cardiovascular or renal diseases, active systemic infections.
* Clinically significant hypoxia (oxygen saturation \< 92% without oxygen supplementation)

Where it's running

• Zhongda Hospital, Affiliated to Southeast University
  Nanjing, Jiangsu, China Recruiting
• Lishui Central Hospital
  Lishui, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Gaojun Teng, M.D — Zhongda Hospital
• Study coordinator: Bill Shen, Ph.D.
• Email: bill.shen@raygene.cn
• Phone: 057185131875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized Neoantigen Vaccine Plus IL-12 in High-Risk Hepatocellular Carcinoma

  This study tests a personalized DNA vaccine plus IL-12 to see if it helps people who have high-risk liver cancer after tumor removal.

  Recruiting at 4 sites Phase 2 Geneos Therapeutics · Atlanta, Georgia and 8 other locations · NCT07722741

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• How genes and alcohol interact to affect liver cancer risk

  This project will test if certain gene variants together with alcohol use and metabolic problems raise the risk of liver cancer in people with fatty or cryptogenic liver disease, especially men with diabetes or obesity.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan, Milano · NCT07272200

• MRI-guided adaptive single-session radiation for liver tumors (SABR)

  This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07223307

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.